Our Parkinson's Place: Normast Add-on Therapy Reduces Motor, Non-motor Symptoms in Parkinson’s Patients, Study Finds

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Monday, May 15, 2017

Normast Add-on Therapy Reduces Motor, Non-motor Symptoms in Parkinson’s Patients, Study Finds

May 15, 2017 06:15 am | Janet Stewart, MSc

Italian researchers found that when used along with standard medication, Normast (ultra-micronized palmitoylethanolamide, or um-PEA) helped lower both motor and non-motor symptoms in patients with advanced Parkinson’s disease (PD), and slowed disease progression and disability.

The study, “Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson’s disease,” appeared in the journal CNS & Neurological Disorders – Drug Targets.

Parkinson’s patients gradually lose control of movement, with symptoms worsening over time. Current medications slow the disease’s progress, but do not stop it. The study says um-PEA is well-known for its ability to fight inflammation of neurons in the brain and protect them. In Italy, um-PEA is marketed as a food under the brand name Normast.

In this study, 30 Parkinson’s patients averaging 73 years of age received 1,200 mg a day of Normast for three months, along with Levadopa (L-DOPA) and other Parkinson’s medications in some cases, and then given 600 mg daily for up to a year.

Researchers used the Motor Disease Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) to evaluate motor and non-motor symptoms of Parkinson’s in their patients. The MDS-UPDRS questionnaire covers four sections: nonmotor aspects of daily living experience, motor aspects of daily living experience, motor examination and motor complications.

After 12 months, non-motor symptoms scores, using the Non-Motor Aspects of Experiences of Daily Living scale, had fallen from 9.7 to 4.5 in patients receiving Normast and Levadopa (L-DOPA). The average score on the Motor Aspects of Experiences of Daily Living scale dropped from 12.7 to 7.6 over the one-year period, while the average total motor complication score dropped from 8.8 to 4.2. Normast caused no side effects.

The researchers said their findings are similar to those from rodent studies.

“Addition of um-PEA to PD patients receiving levadopa therapy elicited a significant and progressive reduction in the total MDS-UPDRS score (parts I, II, III and IV). For each item, the mean score difference between baseline and end of um-PEA treatment showed a significant reduction in most non-motor and motor symptoms. The number of patients with symptoms at basal was reduced after one year of um-PEA treatment,” they reported, concluding that “um-PEA may be an efficacious adjuvant therapy for PD.”

https://parkinsonsnewstoday.com/2017/05/15/um-palmitoylethanolamide-can-slow-down-parkinsons-disease/?utm_source=PAR+E-mail+List&utm_campaign=3ad837d047-RSS_WEEKLY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_62dd4fb5e3-3ad837d047-71459285